US Patent 8,052,987: Zoledronic Acid Patent Scope, Expiration, Orange Book Status, and Generic Risk

US Patent 8,052,987 protects intermittent intravenous administration of zoledronic acid for conditions involving abnormally increased bone turnover. Its commercially important coverage is directed primarily to 5 mg intravenous zoledronic acid administered approximately once yearly for osteoporosis and related bone disorders. The patent does not broadly cover zoledronic acid itself, its chemical synthesis, or every zoledronic acid formulation.

The patent estate was commercially important to Reclast, Novartis’ intravenous zoledronic acid product. Its principal protection was dosing-regimen protection rather than compound protection. The ordinary 20-year patent term reached its end in 2025 based on the patent’s priority framework, subject to any applicable patent-term adjustment. The patent therefore presents limited or no current blocking risk for new generic intravenous zoledronic acid launches after expiration, although historical Orange Book listings and litigation remain relevant to earlier launch dates.

What drug does US Patent 8,052,987 cover?

US Patent 8,052,987 covers zoledronic acid, also known as zoledronate. The chemical name recited in the claims is 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid.

Item	Description
Active ingredient	Zoledronic acid or zoledronate
Drug class	Nitrogen-containing bisphosphonate
Primary product association	Reclast
Other major product association	Zometa
Administration route in claims	Intravenous
Claimed interval	About once yearly, once every two years, or less frequently than once yearly
Claimed therapeutic area	Conditions of abnormally increased bone turnover
Key osteoporosis dose	Approximately 5 mg per administration
Patent owner associated with commercial product	Novartis entities

Zoledronic acid inhibits osteoclast-mediated bone resorption. The claimed method is directed to prolonged antiresorptive treatment using infrequent intravenous dosing rather than daily or weekly oral administration.

What are the independent claims in US Patent 8,052,987?

The patent has three principal independent method claims.

Claim 1: Annual intravenous administration

Claim 1 requires:

A patient with a condition involving abnormally increased bone turnover.
Administration of zoledronic acid, a pharmaceutically acceptable salt, or a hydrate.
Intravenous administration.
Intermittent treatment.
Administration approximately once per year.

Claim 1 is the central annual-dosing claim. It is broad as to the particular bone-turnover condition and does not limit the dose to 5 mg. The claim also does not expressly require osteoporosis, although osteoporosis is separately recited in dependent claim 2.

Claim 7: Administration once every two years

Claim 7 covers intermittent intravenous treatment approximately once every two years. It uses the same active-ingredient and disease-category language as claim 1.

This claim is potentially relevant to long-interval osteoporosis maintenance regimens, retreatment protocols, and other extended dosing schedules. The claim does not require a particular dose, formulation, infusion duration, or clinical endpoint.

Claim 9: Administration less frequently than annually

Claim 9 covers intermittent intravenous administration at an interval less frequent than approximately once a year. This language is broader in timing than claim 7 because it is not limited to a two-year interval.

The practical scope depends on construction of “less frequent than about once a year.” It most naturally covers intervals longer than approximately 12 months, including two-year or longer retreatment schedules.

What dependent claims protect?

Claims 2 through 6 and claim 8 narrow the independent claims by adding disease or dose limitations.

Claim	Added limitation	Practical relevance
2	Osteoporosis	Directly aligns with Reclast’s osteoporosis use
3	Parenteral unit dosage form containing about 1 mg to 10 mg	Captures a broad dose range
4	About 1 mg to 5 mg	Includes the 5 mg dose
5	About 5 mg to 10 mg	Includes doses above 5 mg
6	About 5 mg	Directly targets the commercial 5 mg dose
8	Unit dosage form containing about 1 mg to 10 mg	Narrows the two-year regimen in claim 7

The most commercially significant claim combination is claim 2 or claim 6 read with claim 1. A product using approximately 5 mg of zoledronic acid intravenously once yearly for osteoporosis would fall within the principal commercial target of the patent, assuming the claim remained enforceable and the relevant terms were satisfied.

What formulations are protected by US Patent 8,052,987?

The patent protects use of a unit dosage form adapted for parenteral administration when the claimed dose range is met. It does not appear, from the supplied claims, to require particular excipients, pH, container configuration, concentration, infusion volume, or infusion duration.

The formulation-related scope is therefore limited compared with a conventional composition patent.

Formulation elements included in the claims

The claims expressly cover:

Zoledronic acid;
A pharmaceutically acceptable salt;
Any hydrate;
A parenteral unit dosage form;
Approximately 1 mg to 10 mg in claims 3, 4, 5, and 8;
Approximately 5 mg in claim 6.

Formulation elements not expressly required

The supplied claims do not expressly require:

A 15-minute infusion;
A particular concentration;
A specific diluent;
A specific pH;
Calcium or vitamin D supplementation;
A particular vial or bag;
A particular manufacturing process;
A particular excipient system.

A generic manufacturer could therefore avoid formulation-specific infringement only if its dosing regimen, indication, route, dose, or other claim element falls outside the asserted claim. Changing excipients alone would not avoid a claim directed to the method of administration.

How strong is the patent estate for zoledronic acid?

The patent estate is strongest against a product that matches all of the following characteristics:

Intravenous zoledronic acid;
Approximately 5 mg per dose;
Osteoporosis treatment;
Annual administration;
Marketing or labeling that instructs the claimed regimen.

Its strength is lower against:

Intravenous doses outside the claimed ranges;
Inpatient or oncology uses administered on different schedules;
Single-dose or rescue treatment without recurring annual administration;
Regimens longer than the claimed interval but not characterized as the claimed method;
Products whose labeling omits the protected indication or schedule, subject to induced-infringement analysis.

The patent is not a compound patent. Earlier zoledronic acid composition and use patents, including patents associated with Zometa, had separate expiration dates and claim structures. US 8,052,987’s commercial value came from extending protection around the long-interval administration strategy used for Reclast.

What was the Orange Book status of US Patent 8,052,987?

US Patent 8,052,987 was listed in connection with Reclast, a New Drug Application product containing zoledronic acid injection. The relevant Orange Book category was a method-of-use listing rather than a patent covering the basic chemical compound.

Orange Book issue	Assessment
Listed product	Reclast
NDA holder	Novartis Pharmaceuticals Corporation
Patent type	Method of use
Protected use	Intermittent intravenous zoledronic acid treatment, including osteoporosis-related dosing
Product type	Small molecule
Biosimilar listing	Not applicable
Current strategic significance	Reduced after patent-term expiration

Orange Book listing does not itself establish that every generic product infringes. It identifies patents that the NDA holder represented as relevant to the approved product under the Hatch-Waxman framework. The legal effect depends on the claims, the proposed generic labeling, and the timing of any Paragraph IV litigation.

When did US Patent 8,052,987 lose exclusivity?

The patent’s ordinary 20-year term was tied to its earliest claimed priority date and reached its end in 2025. The exact enforceable end date depends on the patent’s recorded patent-term adjustment and any applicable term calculation under 35 U.S.C. § 154.

The commercial exclusivity timeline was therefore:

Period	Event
Priority and prosecution period	Development and patenting of intermittent zoledronic acid dosing
November 2011	US Patent 8,052,987 issued
Pre-expiration period	Orange Book method-of-use protection constrained matching annual intravenous generic labeling
2025	Ordinary patent term reached its end, subject to any patent-term adjustment
Post-expiration period	Patent-based blocking risk materially declined

The patent was not a perpetual barrier to generic zoledronic acid. Its protection was time-limited and regimen-specific.

Were there Paragraph IV challenges to US Patent 8,052,987?

Generic manufacturers seeking FDA approval before expiration could have challenged the patent through an ANDA Paragraph IV certification. A Paragraph IV certification asserts that the listed patent is invalid, unenforceable, or not infringed.

For this patent, the most likely challenge theories would have included:

Lack of novelty based on earlier bisphosphonate dosing disclosures;
Obviousness based on known zoledronic acid pharmacology and long skeletal retention;
Written-description or enablement challenges to broad intervals such as “less frequent than about once a year”;
Noninfringement based on dose, interval, indication, or labeling;
Failure to satisfy the claim’s requirement for intermittent administration;
Lack of infringement where the generic label did not include the protected osteoporosis regimen.

A Paragraph IV challenge would have created potential Hatch-Waxman litigation and an automatic 30-month stay of FDA approval under applicable conditions. That stay would have applied to the relevant ANDA and listed patent, not to the entire zoledronic acid market.

No current commercial launch should be treated as blocked solely because the patent was previously listed. The patent’s expiration changes the analysis materially.

What patent litigation affected zoledronic acid products?

Zoledronic acid has had separate patent disputes involving:

Compound and chemical-process patents;
Zometa oncology uses;
Reclast osteoporosis uses;
Intravenous dosing schedules;
Generic labeling and method-of-use carve-outs.

US 8,052,987 was commercially relevant because it addressed the annual and extended-interval dosing concept associated with Reclast. Litigation risk would have depended on the generic’s proposed label and whether the ANDA applicant sought approval for osteoporosis, Paget’s disease, oncology indications, or only nonprotected uses.

The absence of a product-level composition patent does not eliminate litigation risk during the patent term. A method-of-use patent can delay approval or force a label carve-out even when the active ingredient is otherwise off-patent.

Does US Patent 8,052,987 create biosimilar risk?

No. Zoledronic acid is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is the ANDA generic pathway, not the abbreviated biosimilar pathway under the Biologics Price Competition and Innovation Act.

The principal regulatory questions were:

Whether the generic product has the same active ingredient;
Whether it is pharmaceutically equivalent;
Whether it has the same route and dosage form;
Whether the applicant can use a section viii statement or must address the listed method-of-use patent;
Whether the proposed label includes the patented osteoporosis regimen.

Which companies compete with Novartis in intravenous zoledronic acid?

Competition has included generic manufacturers and suppliers of zoledronic acid injection. Market participants have included companies such as Teva, Fresenius Kabi, Hikma, Dr. Reddy’s, and other ANDA sponsors, depending on product approvals and commercial availability.

Competition is generally based on:

Wholesale acquisition price;
Hospital and clinic contracting;
Supply reliability;
Vial size and packaging;
Infusion-center distribution;
Reimbursement;
Regulatory approval for oncology and osteoporosis uses.

The major commercial distinction is between Reclast-style osteoporosis treatment and Zometa-style oncology treatment. A generic may compete in one segment while facing separate patent or labeling issues in another.

What generic launch scenarios existed?

Full-label launch after patent expiration

After expiration, an ANDA sponsor could seek approval for the full approved use set, subject to FDA requirements and any remaining unexpired patent or regulatory exclusivity.

Carved-out label before expiration

A generic could attempt to omit the protected osteoporosis regimen while retaining nonprotected indications. This strategy depends on FDA approval of the proposed labeling and whether the remaining instructions induce infringement.

Litigation settlement

A settlement could establish an agreed launch date before or at patent expiration. Any such agreement would require review under antitrust and Hatch-Waxman standards and would not necessarily eliminate other patents.

At-risk launch

A generic could launch before final resolution after obtaining approval, accepting potential damages and injunction risk if the patent owner prevailed. This scenario was materially less attractive as the patent approached its 2025 term end.

What manufacturing and intellectual-property barriers remain?

US Patent 8,052,987 does not appear to create a manufacturing-process barrier from the supplied claims. It claims treatment methods, not synthesis or production steps.

Remaining barriers may include:

Sterile intravenous manufacturing;
Control of particulate matter and impurities;
Container-closure integrity;
Stability of the finished injection;
Bioequivalence and pharmaceutical equivalence;
FDA inspection readiness;
Supply of high-quality zoledronic acid active pharmaceutical ingredient;
Separate process, formulation, or packaging patents;
Regulatory requirements for multiple indications.

The principal patent risk was therefore label and regimen driven, while the principal operational risk was sterile injectable manufacturing.

How does US Patent 8,052,987 compare with other zoledronic acid patents?

Patent category	Typical subject matter	Relevance after 2025
Compound patents	Zoledronic acid chemical entity	Generally expired or near expiration
Process patents	Synthesis, purification, salts, or crystalline forms	Depends on individual patent term
Formulation patents	Injectable composition, stability, packaging	Depends on claim scope and expiration
Method-of-use patents	Osteoporosis, Paget’s disease, cancer-related bone disease	US 8,052,987 is in this category
Dosing-regimen patents	Annual or extended-interval IV administration	Core subject of US 8,052,987
Regulatory exclusivity	FDA orphan, pediatric, or new-use protections	Must be assessed separately from patent term

US 8,052,987 was stronger as a dosing-regimen patent than as a general zoledronic acid patent. A competitor could potentially avoid it through a different indication or schedule during the patent term, but a product intentionally labeled for 5 mg annual intravenous osteoporosis treatment was exposed to its central claims.

Key Takeaways

US Patent 8,052,987 covers intermittent intravenous zoledronic acid treatment.
The main commercial target is approximately 5 mg administered once yearly for osteoporosis.
Claims 7 and 9 extend protection to approximately two-year and longer dosing intervals.
The patent covers methods of treatment, not the basic zoledronic acid molecule or a general manufacturing process.
Dependent claims protect parenteral unit doses ranging from approximately 1 mg to 10 mg, including approximately 5 mg.
The patent was associated with Reclast and operated as an Orange Book method-of-use listing.
Generic risk depended heavily on the proposed label, dosing interval, indication, and Paragraph IV strategy.
Zoledronic acid is a small molecule, so biosimilar rules do not apply.
The ordinary patent term reached its end in 2025, subject to any recorded patent-term adjustment.
After expiration, the principal barriers to generic entry shift from this patent to FDA requirements, injectable manufacturing, supply, and any separate unexpired patents.

FAQs

Is US Patent 8,052,987 a compound patent for zoledronic acid?

No. It is principally a method-of-treatment patent covering intermittent intravenous administration of zoledronic acid at specified intervals.

Does a 5 mg zoledronic acid injection automatically infringe the patent?

No. Infringement requires the relevant claim elements, including the route, patient condition, dosing interval, and method of use. A 5 mg dose alone is insufficient.

Does the patent cover Zometa cancer treatment?

The claims cover conditions of abnormally increased bone turnover, but the supplied claims do not expressly identify cancer or skeletal-related events. Coverage depends on whether the specific treatment satisfies the claim elements and whether another patent is implicated.

Can a generic use the same 5 mg vial with a different dosing schedule?

Potentially. A different schedule may avoid the annual, biennial, or less-frequent-than-annual limitations, but the entire claim must be evaluated, including the proposed labeling and actual use.

Is an Orange Book listing the same as an enforceable patent?

No. An Orange Book listing identifies a patent asserted to be relevant to an approved drug. Enforceability and infringement remain legal questions governed by the patent claims, prosecution history, product labeling, and applicable law.

References

U.S. Patent No. 8,052,987. (2011). Methods for the treatment of conditions of abnormally increased bone turnover. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Reclast prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Zometa prescribing information. FDA.
United States Code, 35 U.S.C. § 154. Patent term.

PCT Information
PCT Filed	June 18, 2001	PCT Application Number:	PCT/EP01/06850
PCT Publication Date:	December 27, 2001	PCT Publication Number:	WO01/97788

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1591122	⤷ Start Trial	CA 2013 00016	Denmark	⤷ Start Trial
European Patent Office	1591122	⤷ Start Trial	C300582	Netherlands	⤷ Start Trial
European Patent Office	1591122	⤷ Start Trial	92174	Luxembourg	⤷ Start Trial
European Patent Office	1591122	⤷ Start Trial	C01591122/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,052,987

Summary for Patent: 8,052,987